In this section
Green-top Guidelines by year published
The guideline provides comprehensive information on risk factors, recommended investigations and treatments for recurrent first trimester and one or more second trimester miscarriages.
Published 19 June 2023
This guideline summarises the evidence regarding the diagnosis, and the maternal and fetal risks of intrahepatic cholestasis of pregnancy (ICP), previously called obstetric cholestasis.
The purpose of this guideline is to review the literature and provide evidence-based guidance on the use of cerclage in women at risk of preterm birth and second trimester loss.
The aim of this guideline is to provide evidence-based recommendations on the use of antenatal corticosteroids in women at risk of preterm birth or undergoing caesarean birth at term.
This guideline sets a series of evidence-based standards to ensure a high level and consistency of practice in the provision and performance of amniocentesis and chorionic villus sampling (CVS).
This guideline describes the presentation, management, treatment and follow-up of gestational trophoblastic disease (GTD) and gestational trophoblastic neoplasia (GTN).
This guideline provides evidence-based information on the use of forceps and vacuum extractor for both rotational and non-rotational operative vaginal deliveries.
This guideline covers the different causes of maternal collapse, the identification of women at increased risk and the management of maternal collapse.
Care after non-invasive pre-natal testing (NIPT)
This is the proposed scope for the new RCOG Green-top Guideline on Non-Invasive Prenatal Testing.
Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24+0 Weeks of Gestation (Green-top Guideline No. 73)
This guideline covers recommendations for the diagnosis, assessment, care and timing of birth of women presenting with suspected PPROM from 24+0 to 36+6 weeks of gestation. It also addresses care in a subsequent pregnancy.
This guideline covers interventions prior to conception, and during and after pregnancy when caring for women with obesity.
This guideline describes the diagnostic modalities and reviews the evidence-based approach to the clinical management of pregnancies complicated by vasa praevia.
This guideline describes the diagnostic modalities and reviews the evidence-based approach to the clinical management of pregnancies complicated by placenta praevia and placenta accreta.
This guideline provides guidance for obstetricians, midwives and neonatologists on the prevention of early-onset neonatal group B streptococcal (EOGBS) disease.
This guideline is intended for both specialist haematologists and obstetricians who have experience in managing pregnant patients with bleeding disorders. In addition, it may be a useful reference text for obstetric anaesthetists and neonatologists.
External Cephalic Version and Reducing the Incidence of Term Breech Presentation (Green-top Guideline No. 20a)
This guideline summarises the evidence regarding the routine use of external cephalic version (ECV) for breech presentation.
This guideline provides up-to-date information on methods of delivery for women with breech presentation.
This guideline provides information about the prevention and management of postpartum haemorrhage (PPH), primarily for clinicians working in obstetric-led units in the UK; recommendations may be less appropriate for other settings where facilities, resources and routine practices differ.
This guideline provides evidence-based information for primary and secondary care clinicians on the symptoms and treatment options for bladder pain syndrome (BPS) in women.
This guideline reviews the diagnosis, classification and management of premenstrual syndrome. In addition, the evidence for pharmacological and nonpharmacological treatments is examined.
This guideline provides clinicians with up-to-date evidence-based information regarding the management of monochorionic twin pregnancy.
This guideline provides evidence-based guidance on the diagnosis and management of ectopic pregnancies.
This guideline provides information on the investigation and management of postmenopausal women with known ovarian cysts.
This guideline summarises the evidence and how to manage women with hyperemesis gravidarum.
This guideline summarises the evidence on maternal and fetal outcomes in women with epilepsy.
This guideline provides clinicians with up-to-date evidence-based information regarding the management of endometrial hyperplasia.
This guideline provides information about the diagnosis and treatment of ovarian hyperstimulation syndrome (OHSS).
This guideline provides evidence-based information to inform the care of women undergoing either planned vaginal birth after previous caesarean section (VBAC) or elective repeat caesarean section (ERCS).
This guideline aims to assist generalist and subspecialist gynaecologists in the management of posthysterectomy vaginal vault prolapse (PHVP). The management of urinary incontinence is not covered in this guideline; however, the role of concomitant continence procedures at the time of surgery for vault prolapse is addressed.
This guideline reviews the evidence on female genital mutilation (FGM) and provides guidance for clinicians involved in the care of women who have undergone FGM.
This guideline provides evidence-based guidance on the diagnosis, management and treatment of third- and fourth-degree perineal tears (obstetric anal sphincter injuries, referred to as OASIS).
This guideline offers guidance about the appropriate use of blood products that neither compromises the affected woman nor exposes her to unnecessary risk. Strategies to maximise the haemoglobin (Hb) level at delivery as well as to minimise blood loss are also discussed.
Thrombosis and Embolism during Pregnancy and the Puerperium: Acute Management (Green-top Guideline No. 37b)
This guideline provides advice on the immediate investigation and management of women in whom venous thromboembolism (VTE) is suspected during pregnancy and the puerperium.
Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk (Green-top Guideline No. 37a)
This guideline provides advice on the prevention of venous thromboembolism (VTE) during pregnancy and birth and following delivery.
This guideline assesses the evidence regarding the maternal and fetal risks of varicella zoster virus (VZV) infection in pregnancy and whether these complications can be prevented or modified by the administration of varicella zoster immune globulin (VZIG) or by treatment with aciclovir.
This guideline provides information based on clinical evidence about the long-term health consequences of PCOS.
This guideline provides evidence-based advice on the prevention, diagnosis and management of umbilical cord prolapse.
This guideline aims to assist clinicians with the initial assessment and appropriate management of pregnant women with red blood cell antibodies.
This guideline provides evidence-based guidance on the management of women with beta (β) thalassaemia major and intermedia in pregnancy.
This guideline reviews the risk factors for a small-for-gestational-age (SGA) fetus and provides recommendations regarding screening, diagnosis and management, including fetal monitoring and delivery.
This guideline provides an evidence-based summary for the generalist to facilitate appropriate investigation and management of women presenting for the first time with chronic pelvic pain.
This guideline covers the recognition and management of serious bacterial illness in the antenatal and intrapartum periods and its management in secondary care.
This guideline provides guidance in the management of sepsis in the puerperium (sepsis developing after birth until 6 weeks postnatally).
This guideline reviews the evidence regarding the possible prediction, prevention and management of shoulder dystocia.
This guideline provides advice for clinicians working in obstetric units on how to deal with antepartum haemorrhage.
This guideline aims to assist clinicians with the initial assessment and appropriate management of suspected ovarian masses in premenopausal women.
This guideline describes the management of pregnant women with sickle cell disease, including preconceptual screening and antenatal, intrapartum and postnatal management.
This guideline has been archived. Please see the guideline produced by the Faculty of Sexual and Reproductive Healthcare (FSRH).
This guideline has been archived. Please see Green-top Guideline No. 75 Cervical cerclage and the NICE guideline [NG25] Preterm labour and birth.
This guideline provides guidance on the investigation and treatment of couples with three or more first-trimester miscarriages, or one or more second-trimester miscarriages.
This guideline summarises the evidence for the fetal risks associated with obstetric cholestasis and provides guidance on the different management choices and the options available for its treatment.
This guideline has been archived. Please see the British Committee for Standards in Haematology (BCSH) guideline on anti-D administration in pregnancy.
This guideline provides clinicians with evidence-based information regarding outpatient hysteroscopy, with a focus on minimising pain and optimising the woman’s experience.
This guideline reviews the risk factors for reduced fetal movements in pregnancy and makes management recommendations
This guideline has been archived. Please see the British Association for Sexual Health and HIV (BASHH) guideline on the management of vulval conditions.
This guideline has been archived. Please see the NICE guideline [NG25] Preterm labour and birth.
This guideline identifies evidence-based options for women who have a late intrauterine fetal death of a singleton fetus.
This guideline has been archived. Please see the NICE guideline [NG25] Preterm labour and birth.
This guideline has been archived. Please see GTG No. 73 Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes, and the NICE guideline [NG25] Preterm labour and birth.
This guideline has been archived. Please see the Faculty of Sexual and Reproductive Healthcare (FSRH) statement on venous thromboembolism and hormonal contraception.
This guideline provides clinicians with evidence-based information on the diagnosis and treatment of malaria in pregnancy in situations likely to be encountered in UK medical practice.
This guideline provides clinicians with evidence-based information about the prevention of malaria in pregnancy in situations likely to be encountered in UK clinical practice (i.e. in UK residents visting malaria endemic areas).
How Green-top Guidelines are developed
The Green-top Guidelines are produced following the process outlined in the handbook Developing a Green-top Guideline: Guidance for developers (PDF 2.4mb), under the direction of the RCOG Guidelines Committee.
NICE has accredited the process used by the RCOG to produce its Green-top Guidelines. Accreditation is valid for 5 years from June 2020. More information on accreditation can be viewed at http://www.nice.org.uk/about/what-we-do/accreditation.
Above, you can browse Green-top Guidelines by title or year published.
For any enquiries about Green-top Guidelines, please contact email@example.com.
The recommendations are not intended to dictate an exclusive course of management or treatment.
They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice.